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Background: Biotransformation is an effective technique for the synthesis of libraries of bioactive compounds.
Current study on microbial transformation of dihydrotestosterone (DHT) (1) was carried out to produce various
functionalized metabolites.
Results: Microbial transformation of DHT (1) by using two fungal cultures resulted in potent butyrylcholinesterase
(BChE) inhibitors. Biotransformation with Macrophomina phaseolina led to the formation of two known products,
5α-androstan-3β,17β-diol (2), and 5β-androstan-3α,17β-diol (3), while biotransformation with Gibberella fujikuroi
yielded six known metabolites, 11α,17β-dihydroxyandrost-4-en-3-one (4), androst-1,4-dien-3,17-dione (5), 11α-
hydroxyandrost-4-en-3,17-dione (6), 11α-hydroxyandrost-1,4-dien-3,17-dione (7), 12β-hydroxyandrost-1,4-dien-3,17-
dione (8), and 16α-hydroxyandrost-1,4-dien-3,17-dione (9). Metabolites 2 and 3 were found to be inactive, while
metabolite 4 only weakly inhibited the enzyme. Metabolites 5–7 were identified as significant inhibitors of BChE.
Furthermore, predicted results from docking simulation studies were in complete agreement with experimental
data. Theoretical results were found to be helpful in explaining the possible mode of action of these newly
discovered potent BChE inhibitors. Compounds 8 and 9 were not evaluated for enzyme inhibition activity both
in vitro and in silico, due to lack of sufficient quantities.
Conclusion: Biotransformation of DHT (1) with two fungal cultures produced eight known metabolites. Metabolites
5–7 effectively inhibited the BChE activity. Cholinesterase inhibition is among the key strategies in the management
of Alzheimer’s disease (AD). The experimental findings were further validated by in silico inhibition studies and
possible modes of action were deduced.
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Butyrylcholinesterase (BChE) inhibition, Alzheimer’s disease, Molecular docking simulationBackground
Microbial transformation of steroids is being studied for
decades but the need to develop new structural ana-
logues remain strong due to multiple reasons, including
quest for medicinally important novel steroids [1]. In
continuation of our recent work on the microbial trans-
formation of important steroids [2], we investigated the
microbial biotransformation of DHT. The rationale was* Correspondence: salman.hej@gmail.com; iqbal.choudhary@iccs.edu
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reproduction in any medium, provided the orto produce the DHT analogues for studying the structure-
activity-relationship (SAR) and to synthesize medicinally
important compounds with novel activities.
DHT (1) Figure 1, plays a vital role in the growth and
differentiation of ventral prostate. DHT is selectively
retained by an androgen receptor, found in the nuclear
chromatin of prostate [3]. Due to its weaker interaction
with the androgen receptor as compared to testosterone,
DHT has a stronger androgenic potency [4]. It also plays
a vital role in human hair loss [5].
Butyrylcholine (BCh) is an acetylcholine-like com-
pound (Figure 1), hydrolyzed by acetylcholinesterase
(AChE) and BChE (pseudocholinesterase), the latter be-
ing more efficient. BCh is a synthetic compound, used asl Ltd. This is an open access article distributed under the terms of the Creative
commons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 2 Biotransformation of dihydrotestosterone (1) with
Macrophomina phaseolina.
Figure 1 Structures of compounds used in the current study.
Zafar et al. Chemistry Central Journal 2013, 7:164 Page 2 of 12
http://journal.chemistrycentral.com/content/7/1/164a tool to distinguish between acetyl- and BChEs. BChEs
is essential for the catalysis of the rapid breakdown of
suxamethonium (succinylcholine), a muscle relaxant,
frequently used in surgery and electroshock therapy.
Prolonged muscle relaxation may follow the administra-
tion of drug if pseudocholinesterase activity is defective
or markedly decreased [6,7]. BChE inactivates the neuro-
transmitter, acetylcholine (ACh). ACh is an important
therapeutic target for the treatment of Alzheimer’s dis-
ease, characterized by a cholinergic deficit [8].
DHT was subjected to microbial transformation with
two fungal cultures, Macrophomina phaseolina and
Gibberella fujikuroi and eight known metabolites 2–9
were obtained. Substrate 1 and its metabolites 2–7 were
subjected to AChE and BChE inhibitory activity evaluation.
All compounds were found to be inactive against AChE,
while metabolite 5–7 have significantly inhibited the BChE.
Compounds 8 and 9 were not subjected to the above men-
tioned activity due to lack of sufficient quantities.
Protein-ligand docking programs are used for the
placement of small molecules within the binding pocket
of target proteins (receptors) and to rank them
according to their binding affinity [9,10]. In current study,
biotransformed products 2–7 were also evaluated in silico
to understand their mode of interaction with the BChE.
Resolved crystal structure of BChE was used in molecular
docking simulation studies. All biotransformed metabo-
lites were docked within the binding pocket of the crystal
structure of human BChE (PDB ID 1P0P: 2.30 Å), reveal-
ing structural features, responsible of observed enzyme in-
hibitory activities [11]. MOE docking software was utilized
to perform the molecular docking experiment. The out-
come of the docking study helped to understand the bind-
ing mechanism of compounds with BChE.
Results and discussion
This is the first report of microbial transformation of
DHT (1) (Figure 1), (C19H30O2) with M. phaseolina and
G. fujikuroi. Fermentation of compound 1 with M.
phaseolina for 6 days led to the formation of two knownmetabolites 2 and 3 (Figure 2), while 7 days fermenta-
tion of 1 with G. fujikuroi yielded six known metabolites
4–9 (Figure 3). Structure elucidation of all metabolites is
presented below.
Metabolites identification
Metabolite 2 (C19H32O2) (M
+ m/z 292.2434, calcd
292.2402) showed no florescence under UV light. The
IR spectrum exhibited an absorption at 3350 cm-1
(OH), but no absorption for the ketone group was
observed. This suggested that the 2 atomic mass units
(a.m.u.) increase in the molecular weight might be due
to the reduction of the ketone group of substrate 1 to a
hydroxyl group in 2.
The 1H-NMR spectrum of 2 showed two hydroxyl-
bearing methine signals at δ 3.49 (m, H-3), and 3.54
(t, J17a,16a,e = 8.4 Hz, H-17). The second hydroxyl signal
was resulted from the reduction of the ketone at C-3.
The 13C-NMR spectrum had two hydroxyl-bearing
Figure 3 Metabolites of biotransformation of DHT (1) with
Gibberella fujikuroi.
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3.49) showed HMBC correlation with C-5 (δ 46.3). H-5
(δ 1.10, m) also showed HMBC cross peaks with C-3
(δ 71.8) and C-10 (δ 36.7). The NOESY interactions
between H-3 (δ 3.49) and H-5 (δ 1.10), as well as
between H-5 and H-9 (δ 0.64, ddd, J9a,8a = 14.8 Hz,
J9a,11a = 10.8 Hz, J9a,11e = 4.4 Hz), indicated the α-orientation
(axial) of H-3. H-17 (δ 3.54) showed NOESY interac-
tions with H-14 (δ 0.92), suggesting its α-orientation
(Additional file 1). The metabolite 2 was thus character-
ized as 5α-androstan-3β,17β-diol. The compound 2 has
been earlier derived from DHEA (dehydroepiandroster-
one) by the action of 17β-hydroxysteroid dehydrogenase
type 7 enzyme [12]. 5α-Androstan-3β,17β-diol (2) has
been reported to inhibit lipopolysaccharide induced
inflammatory response and tumor necrosis factor in
human endothelial cells [13].
The metabolite 3, C19H32O2 [M
+ =m/z 292.2434 (calcd
292.2402)], was UV inactive, thus lacked α,β-unsaturated
carbonyl system. The IR spectrum indicated the presence
of -OH (3349 cm-1), but no ketonic absorption. This could
be due to the reduction of the carbonyl group at C-3.
The 1H-NMR spectral analysis indicated two hydroxyl-
bearing methine-proton triplets at δ 3.94 (J3a,2/4 =
2.4 Hz, H-3), and 3.55 (J17a,16a,e = 8.8 Hz, H-17), with
their respective carbons resonated at δ 67.2 and 82.6, re-
spectively, in the 13C-NMR spectrum (HMQC). HMBC
of H-5 (δ 1.48) with carbon at δ 67.2 indicated the re-
duction of C-3 carbonyl into an OH. The H-3 (δ 3.94)
showed NOESY correlation with H-5 (δ 1.48). Interest-
ingly H-5 did not show any NOESY cross peak with H-9(δ 0.74), indicating that H-5 is not α-oriented. Compari-
son of the 1H- and 13C-NMR chemical shift data of C-3
and C–5 of metabolites 2 and 3 showed marked differences
which may be due to differences in the stereochemistry at
these positions (Additional file 2). The metabolite was fi-
nally identified as 5β-androstan–3α,17β-diol, reported earl-
ier as a biotransformation product of testosterone by
fungus Exophiala jeanselmei [14].
The molecular formula C19H28O3 [M
+, m/z 304.2058]
of metabolite 4 was deduced from the HREI-MS (calcd
304.2038). The presence of hydroxyl (3437 cm-1) and
carbonyl (1667 cm-1) groups was inferred from the IR
spectrum, while UV spectrum also indicated a conju-
gated ketone (λmax = 233 nm).
The 1H-NMR analysis of 4 displayed some new signals
as compared to the starting material DHT (1). A down-
field methine signal at δ 4.02 (br. s, W1/2 = 22.0 Hz) and
its respective carbon at δ 68.9, indicated the hydroxyl-
ation of one of the methylene carbon atoms. A
downfield olefinic proton singlet at δ 5.71 (s) and the
corresponding carbon at δ 124.6 indicated the introduc-
tion of a C = C bond. The HMBC spectrum displayed
long-range couplings of the hydroxyl-bearing methine
proton (δ 4.02) with C-9 (δ 59.2), C-10 (δ 39.9), and C-
13 (δ 43.7), which suggested the position of the -OH at
C-11. The stereochemical assignments were based on
NOESY interactions between H-11 (δ 4.02), H-8 (δ
1.56), Me-19 (δ 1.31) and Me-18 (δ 0.81). H-11 was thus
deduced as β-oriented. The olefinic proton (δ 5.71)
showed HMBC with C-10 (δ 39.9), and C-2 (δ 34.2).
The enone system was thus deduced at C-3/C-4-C-5, with
the olefinic proton at C-4 (Additional file 3). Metabolite 4
was identified as 11α,17β-dihydroxyandrost-4-en-3-one.
Hunter et al. in 2009 reported metabolite 4 from biotrans-
formation of testosterone with fungus Myceliophthora
thermophila [15], in an organotypic culture which repre-
sents in vivo situation. The cultures consisted of primary
rat, porcine, and human hepatocytes [16].
Metabolite 5 (C19H24O2 M
+ at m/z 284.1726, calcd
284.1776) showed the presence of ketone (1730 cm-1)
and a conjugated enone (1657 cm-1) in IR spectrum. UV
spectrum showed a strong absorption for conjugated
ketone (λmax = 243 nm).
The 1H-NMR analysis of 5 showed three olefinic sig-
nals at δ 7.03 (d, J1,2 = 10.4 Hz), 6.22 (d, J2,1 = 10.4 Hz)
and 6.07 (s). Their corresponding carbons were reso-
nated at δ 155.3, 127.7, and 124.2, respectively. The 13C-
NMR spectrum was devoid of any OH-bearing carbon
signal which suggested the oxidation of the hydroxyl at
C-17 into a ketone carbonyl. The conjugated ketonic
group, inferred from UV analysis, was placed at C-3.
The 13C-NMR spectra (Table 1) showed two ketonic car-
bonyl signals at δ 186.3 and 220.1 (Additional file 4).
Metabolite 5 was thus characterized as androst-1,4-dien-
Table 1 13C-NMR Chemical shift data of compounds 1–9,
δ in ppm
Compounds
C 1 2 3 4 5 6 7 8 9
1 38.7 38.3a 32.9 37.5 155.3 37.4 158.6 155.1 155.0
2 38.2 32.1 30.6 34.2 127.7 34.1 125.1 127.8 127.8
3 211.8 71.8 67.2 200.3 186.3 199.9 186.7 186.2 186.2
4 44.5 38.9 36.7 124.6 124.2 124.8 124.8 124.3 124.2
5 46.8 46.3 40.4 170.9 168.3 170.1 167.4 167.9 167.9
6 28.9 29.9 29.6 33.6 32.5 33.3 32.8 32.5 32.4
7 31.3 32.9 33.5 31.1 32.3 30.3 32.1 33.4 31.9
8 35.6 36.9 36.9 35.3 35.1 34.6 33.9 34.4 35.0
9 53.8 56.0 56.1 59.2 52.2 59.2 60.4 52.1 51.9
10 35.8 36.7 37.2 39.9 43.4 40.0 43.9 43.4 43.3
11 21.0 21.9 21.5 68.9 22.1 68.7 67.7 36.1 21.7
12 36.8 38.1a 38.1 48.5 31.1 42.9 42.3 86.0 30.9
13 43.1 44.1 44.1 43.7 47.7 47.9 47.8 42.7 38.7
14 50.9 52.4 52.5 49.8 50.4 50.0 49.6 44.1 47.3
15 23.5 24.3 24.3 23.3 21.9 21.7 21.8 22.2 30.6
16 30.6 30.6 29.7 30.6 35.6 35.7 35.8 35.5 71.1
17 81.9 82.5 82.6 81.0 220.1 218.4 218.3 216.2 218.3
18 11.1 11.7 11.7 12.3 13.8 14.6 14.6 11.5 14.1
19 11.5 12.8 11.6 18.4 18.7 18.3 18.7 18.7 18.7
Note:
a interchangeable δ values.
CDCl3 at 125 MHz (1, 6).
CDCl3 at 150 MHz (4, 5, 7, 8, 9).
CD3OD at 150 MHz (2).
CD3OD at 100 MHz (3).
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ite of testosterone [17]. Compound 5 was also previ-
ously obtained from the transformation of testosterone
with Steroidobacter denitrificans strain FST under de-
nitrifying conditions [18]. Soyabean phytosterols also
yielded the same compound upon biotransformation
with Mycobacterium neoaurum [19]. A mutant strain of
Mycobacteriumsp SH5 was utilized to convert phytos-
terols to androst-1,4-dien-3,17-dione [20]. Cholesterol
was converted to compound 5 by biotransformation
with bacteria Chryseobacterium gleum [21].
Metabolite 6 (C19H24O3, M
+ at m/z 302.1852, calcd
302.1882) showed the UV absorption at 234 nm for a
conjugated ketone. The IR spectrum of 6 showed ab-
sorptions at 1668 (C = C-C =O), 1730 (C = O), and
3451 cm-1 (OH).
A methine proton at δ 4.04 (m, W1/2 = 21.5 Hz) was
observed in the 1H-NMR spectrum of 6, while its corre-
sponding methine carbon resonated at δ 68.7 (C-11) in
the 13C-NMR spectrum (Table 1). The COSY spectrum
analysis indicated interactions between H-11 (δ 4.04)
and H-9 (δ 1.15). The H-11 (δ 4.04), also showed HMBCcross peaks with C-13 (δ 47.9), C-10 (δ 40.0), and C-8 (δ
34.6), while NOESY cross peaks were observed between
H-11 (δ 4.04), H-8 (δ 1.68), H-18 (δ 0.92), and H-19 (δ
1.31). Based on the above NOESY interactions, H-11
was assigned a β-orientation (Additional file 5).
Complete spectral analysis indicated that the metabolite
6 was 11α-hydroxyandrost-4-en-3,17-dione. Koshimura
and coworkers obtain compound 6, by hydroxylation of
androstenedione with Gelasinospora retispora [22]. Bio-
transformation of testosterone with Fusarium lini also
afforded the same compound [23].
Molecular formula C19H24O3 (M
+ m/z 300.1749) was de-
duced from the HREI-MS of metabolite 7 (calcd 300.1725).
The UV analysis suggested a conjugated enone system
(λmax 244 nm), while IR spectrum showed absorptions at
3386 (OH), 1731 (C =O) and 1658 cm-1 (C =C-C =O).
The 1H-NMR spectrum of metabolite 7 showed a
downfield hydroxyl-bearing methine proton signal at δ
4.08, which was assigned to H/C-11. C-11 resonated at δ
67.7 in the 13C-NMR spectrum (Table 1) of 7. Three ole-
finic protons appeared at δ 7.73 (d, J1,2 = 10.2 Hz), 6.14
(d, J2,1 = 10.2 Hz) and 6.08 (s), with respective carbons
resonated at δ 158.6, 125.1, and 124.8 (Additional file 6).
Based on the above spectral data and comparison with the
literature [17], metabolite 7 was identified as 11α-hydroxy-
androst-1,4-dien-3,17-dione, earlier obtained from the
biotransformation of testosterone with Fusarium lini [23].
A strain of Trichoderma hamatum was utilized for the
production of 7 from testosterone, testosterone propionate,
androstenedione, 1-dehydrotestosterone, dianabol and pro-
gesterone [24].
Metabolite 8 (C19H24O3, M
+ m/z 300.1737, calcd
300.1725) showed UV absorption at 245 nm. The IR
spectrum showed absorptions at 3389 (OH), 1730 (C =
O) and 1658 cm-1 (C = C-C = O).
Metabolites 7 (Table 1) and 8 (Table 1) have structural
similarities as evident from their NMR spectra. A
methine proton at δ 3.73 (br. s, W1/2 = 13.0 Hz) was ob-
served in the 1H-NMR of 8 (C at δ 86.0). The enone sys-
tem in ring A of compound 8 showed the same HMBC
interactions as in 7. The C-17 ketone carbon (δ 216.2)
showed HMBC correlation with the downfield C-12
methine proton (δ 3.73). The OH-bearing methine C-12
(δ 86.0) showed HMBC correlations with H-9 (δ 1.26),
H-14 (δ 1.48), and CH3-18 (δ 0.78). The H-12 (δ 3.73)
showed NOESY cross peaks with H-14 (δ 1.48), and
H-9 (δ 1.26), and thus supported an α-orientation of
H-12 (Additional file 7). The metabolite 8 was finally
identified as 12β-hydroxyandrost-1,4-dien-3,17-dione,
earlier isolated from Halorrhena wulfsbergii leaves
[25]. Deoxycholate and β-sitosterol were previously
converted to compound 8 by using immobilized
Pseudomonas sp. and a thermophilic bacterium, re-
spectively [26].
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+ =m/z 300.1749, calcd
300.1725), showed UV of 245 nm, while the IR spectrum
displayed the same pattern as 8 [(3388 (OH), 1730,
1657 cm-1 (C = O)) for hydroxyl, ketone and enone func-
tionalities, respectively].
The comparison of 1H-NMR spectra of 9 and 8
showed similarities, except for a methine signal at δ 4.36
(br s, W1/2 = 22.3 Hz) in compound 9 which appeared at
δ 3.73 in metabolite 8. The 13C-NMR spectrum (Table 1)
of 9 showed this new methine carbon at δ 71.1. The pro-
ton, geminal to the -OH group (δ 4.36), was correlated
with C-13 (δ 38.7), C-14 (δ 47.3) and C-17 (δ 218.3) in
HMBC spectrum. The methine C-15 (δ 71.1) showed
HMBC correlations with H-14 (δ 1.50) and H2-15
(δ 1.87, 1.98). Based on the above observations, the
hydroxyl-bearing methine carbon was assigned to C-16.
The H-16 (δ 4.36) showed NOESY cross peaks with H-
18 (δ 1.01), but no interaction with H-14 (δ 1.50).
Therefore the C-16 proton was deduced to be β-
oriented (Additional file 8). The metabolite 9 was thus
identified as 16α-hydroxyandrost-1,4-dien-3,17-dione.
Numazwama et. al., prepared 16α-hydroxyandrost-1,4-
dien-3,17-dione (9) from androst-1,4-dien-3,17-dione
upon reaction with hypervalent iodine [27].
Enzyme inhibition assay
Enzyme inhibition assay was carried out by using spec-
trophotometric method in 96-well plate. The experi-
ments were conducted in triplicate. Substrate 1 showed
a weak inhibition of the AChE. Therefore the substrate
and its metabolites 2–7 were tested for AchE and BChE
inhibitory activity. Interestingly all metabolites were
found inactive against AChE. Metabolite 2 and 3 were
also found to be inactive against the BChE, while metab-
olites 4–7 showed significant selective inhibition of
BChE. Metabolites 5–7 were found to be the most active
members (Table 2). Metabolites 2 and 3 lack a conju-
gated ketone system, while rest of the metabolites (i.e.
4–7) have a α,β-unsaturated ketone system. The activity
might be attributed to the presence of a conjugatedTable 2 BChE Inhibitory activities (IC50) of compounds 1-7








Galanthamine (positive control) 4.9 ± 0.3
aData are expressed as mean ± standard error of mean.
bNot active.system which may help the molecule attain a suitable
configuration for binding to the active site of BChE. Me-
tabolites 4–7 have approximately the same structural
features, with conjugated ketone functionalities and
hydroxyl groups, except 5. Galanthamine was used as a
standard inhibitor in the assay. Galanthamine is a
potent cholinesterase inhibiting (approved by FDA in
2001) drug, which is used in clinical practices for the
management of AD [28], Galanthamine is extensively
used as standard to compare the potency of test com-
pounds (IC50) [29] in biochemical assays. In docking
study (Figure 4), galanthamine can bind to Trp 82 (an-
ionic site) like active compounds 4-7, it means binding
site for compounds and galanthamine is similar, there-
fore all compounds can be compared with standard in
both potency and function.
Molecular docking simulation
Initially, selection of suitable docking program for our
target of interest was possible by re-docking with GOLD,
MOE, and Surflex programs. In this exercise, re-docking
protocol was applied on co-crystallized structure of hu-
man BChE (PDB ID 1P0P). The competency assessment
of each re-docked pose was evaluated by considering the
Root-mean-square deviation (RMSD) values, binding en-
ergy and refinement based re-scoring function, as shown
in Table 3. MOE-Dock is able to produce the most
convincing re-docking results for cognate ligand within
the binding pocket of BChE (Figure 4, Table 4). Co-
crystallized ligand and its re-docked pose are surrounded
by the same active site residues displaying conserved in-
teractions within 0.655 Å RMSD value. On the basis of
satisfactory re-docking results, MOE was utilized to in-
vestigate the behavior of all bio-transformed DHT deriv-
atives 2–7 inside the binding pocket of BChE.
Molecular docking studies demonstrated that all com-
pounds were well accommodated inside the binding
pocket of BChE. Due to the larger binding pocket of
BChE, bulkier compounds like DHT derivatives are eas-
ily placed themselves inside the binding gorge. The best
selected dock pose of galanthamine, used as standard in-
hibitor, exhibited hydrogen bond interaction with cata-
lytic triad residue Glu197 at 2.16 Å with all possible
conserved interactions within 5.0 Å (Figure 5). From the
analysis of various inhibitors (1–7), we conducted that
due to lack of carbonyl moiety and a double bond in
ring “A”, compounds 1–3 were not able to productively
engage with the enzyme, the outcome was well corre-
lated with experimental results. Both functional groups
actively participated in the inhibition of BChE activity
and are involved in the interactions with key residues, as
shown in the Figure 6. The presence of both the
functional groups in compounds seems to be prerequis-
ite to inhibit the BChE activity. From this postulation,
Figure 4 Three Dimensional (3D) conformational differences of co-crystallized ligand (BCH) and its docked pose within binding site
of 1p0p.
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Depth analysis exhibited the role of double bond in
assisting the compound to attain a favorable orientation
towards the binding residue TRP82 which is involved in
the inhibition and thus participate in π-π interaction
between the DHT derivatives and BChE. In active site,
two most important residues of BChE (TYR128 and
TYR332) are frequently involved in hydrogen bonding
and play an important inhibitory role. By docking ex-
periment, SER198, GLU197, HIS438, TYR128, TYR332,
PRO285, PHE329, GLY115, GLY439 and TRP82 were
identified as key residues, located within the binding
pocket of BChE.
The Figure 6c clearly reflects that no interactions were
found between compound3 and binding residues of
BChE, which might be due to the inverted orientation.
Compound 3 exhibited no inhibition of the enzyme
during the experimental studies. Similarly, compounds 1
and 2 also exhibited weak potency against BChE. By
comparison of docked pose orientation of all com-
pounds, it was deduced that compound 2 (Figure 6b)
has a better orientation than compounds 1, and 4–7.
With this orientation, two hydrogen bonds formation
were also possible with the TYR128 (2.89 Å) and
TYR332 (2.17 Å) residues of BChE, but the molecule
would be disorientated for inhibition. This disturbance
could be due to the presence of hydroxyl group (OH),
instead of carbonyl moiety, and the absence of a double
bond in ring “A” that was required for π-π interactions.
Compound 4 was found to be more active as comparedTable 3 Re-docking score of co-crystallized ligand
butyrylthiocholine (BCh) inside the binding pocket of
BChE (PDB ID 1P0P)
Serial number Conformations Binding free
energy (Kcal/mol)
RMSD (Ǻ)
1 BCh −13.11 1.96
2 BCh −11.32 1.51
3 BCh −13.91 0.65to 1–3, while less active than compounds 5–7. It would
be due to the absence of hydrogen bonding with
TYR332 (Figure 6d) even though it is involved in π-π
interaction with TRP82. Compound 7 exhibited the
highest inhibitory potency, experimentally and theoretic-
ally (−6.82 Kcal/mol), due to the double bond in ring
“A”, as well as hydrogen bond interactions with TYR128
(3.19 Å) and TYR332 (3.05 Å) and hydrophobic interac-
tions with key residues.
Docking results of compounds 2–7 with BChE pro-
vided valuable information about the nature of the
binding interactions that were satisfactorily correlated
with the experimental studies. This information could
be utilized to design new leads against the BChE.
Experimental
General
DHT was purchased from Acros-organics (Belgium).
Thin layer chromatography was performed on precoated
silica gel plates (PF254), purchased from Merck (Germany).
Flash silica (E. Merck, Germany) was used for conducting
column chromatography (CC). GS-320 (size exclusion)
column was used for purification of compounds on pre-
parative HPLC. 1H- and 13C-NMR experiments were
conducted in CDCl3 and CD3OD on BrukerAvance-NMR
spectrophotometers. The chemical shifts (δ values) are
presented in ppm and the coupling constants (J values) in
Hertz. JEOL JMS-600H mass spectrometer (Japan) was
used for recording EI-MS in m/z (rel. %).
Microorganisms and culture medium
Macrophomina phaseolina (KUCC 730), obtained from
Karachi University Culture Collection (KUCC), was
grown on Sabouraud dextrose-agar (SDA) at 25°C and
stored at 4°C. The medium for M. phaseolina was pre-
pared by dissolving glycerol (10.0 mL), KH2PO4 (5.0 g),
glucose (10.0 g), yeast extract (5.0 g), NaCl (5.0 g), and
peptone (5.0 g) per litre of distilled H2O.
Gibberella fujikuroi (ATCC 10704) was purchased
from the American Type Culture Collection. One litre
Table 4 Molecular docking studies of biotransformed








1 Inactive NAc −6.64
2 Inactive NAc −6.73
3 Inactive NAc −6.43
4 Active 109.4 ± 1 −6.70
5 Active 11.8 ±0.5 −6.74
6 Active 20.5 ±0.2 −6.57
7 Active 12.9 ±0.7 −6.82
Galanthamine
(Standard)
Active 4.9 ± 0.3 −6.26
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of glucose (20.0 g), NH4NO3 (1.0 g), KH2PO4 (5.0 g),
MgSO4.7H2O (1.0 g) and trace element solution
(2.0 mL). The trace element solution comprised of Co
(NO3)3 (0.01 g), FeSO4.7H2O (0.1 g), CuSO4.5H2O
(0.1 g), ZnSO4.7H2O (0.16 g), MnSO4. 7H2O (0.01 g),
Mo(NH4)3 (0.01 g) in 100 mL distilled water.
Fermentation of DHT (1)
Fermentation with Macrophomina phaseolina The
fermentation medium for M. phaseolina was prepared
by following the procedures presented above. 4.0 Litres
of the medium was prepared and distributed (100 mL
each) among 40 conical flasks (250 mL). The flasks were
plugged with cotton and autoclaved at 121°C. The
sterilized medium was innoculated with spores of M.
phaseolina, obtained from already prepared slants on
SDA. The flasks were placed on rotary shaker, and when
enough growth was achieved, the flasks were fed uni-
formly with 1 g of DHT (1), dissolved in 20 mL acetone
under aseptic conditions. The flasks were left over rotary
shaker for 6 days. The fungal mass was filtered off. The
filtrate was extracted with 12 L of dichloromethane
(DCM). The DCM extract was dried over anhydrous
Na2SO4, and concentrated on a rotary evaporator to ob-
tain a brown gummy material (1.4 g). This gum was
fractionated on a silica gel column with gradient petrol-
eum ether- acetone solvent system. Three main fractions
were obtained, which on further column chromatog-
raphy led to the purification of metabolites 2 and 3.
Microbial transformation of DHT (1) with M.
phaseolina The 13C-NMR chemical shifts of compounds
2 and 3 are shown in Table 1. Other data is presented
below:
5α-Androstan-3β,17β-diol (2). Colorless crystalline
solid. M.p.: 153–155°C (154–157°C [30]). [α]25D : -72.0,c = 0.034, MeOH (+6.20, c = 0.55, CHCl3 [31]).
1H-NMR
(CD3OD, 400 MHz): δ 0.97, m, 1.72
a, m (H-1); 1.38, m,
1.73a, m (H-2); 3.49, m (H-3); 1.26, m, 1.50, m (H-4);
1.10, m (H-5); 1.28a, m, 1.31a, m (H-6); 0.89, m, 1.68, m
(H-7); 1.40, m (H-8); 0.64, ddd (J9a,8a = 14.8 Hz, J9a,11a =
10.8 Hz, J9a,11e = 4.4 Hz) (H-9); 1.30
a, m, 1.56a, m
(H-11); 1.02, m, 1.79, m (H-12); 0.92, m (H-14); 1.24,
m, 1.57a, m (H-15); 1.45, m, 1.95, m (H-16); 3.54, t
(J17a,16a/16e = 8.4 Hz) (H-17); 0.71, s (H-18); 0.83,
s (H-19), (a = exchangeable assignments). 13C-NMR
(CD3OD, 150 MHz): See Table 1, HREI-MSm/z (mol.
formula, calcd value): 292.2434 (C19H32O2, 292.2402).
EI-MSm/z (rel. int., %): 292 [M+] (100), 277 (49), 259
(29), 248 (25), 233 (88), 215 (82), 201 (14), 175 (9), 165
(52), 121 (31), 107 (41), 55 (12).
5β-Androstan-3α,17β-diol (3). Colorless crystalline
solid. M.p.: 229–231°C (230–231°C [32]). [α]25D : + 23.0,
c = 0.028, MeOH (+ 26.0, ethanol [33]). 1H-NMR
(CD3OD, 400 MHz): δ 1.66, m, 1.82, dt (J1a,1e = 12 Hz,
J1a,2a/2e = 3.6 Hz) (H-1); 1.35, m; 1.69, m (H-2); 3.94, t
(J = 2.4 Hz) (H-3); 1.45a, m; 1.59, m (H-4); 1.48a, m (H-
5); 1.28a, m; 1.31, m (H-6); 1.27a, m; 1.39, m (H-7); 1.21,
m (H-8); 0.74, m (H-9); 1.41, m; 1.47a, m (H-11); 0.99,
m; 1.93, m (H-12); 0.89, m (H-14); 1.27a, m; 1.43, m (H-
15); 1.46a, m; 1.56, m (H-16); 3.55, t (J17a,16a/16e = 8.8 Hz)
(H-17); 0.71, s (H-18); 0.82, s (H-19), (a = exchangeable
assignments). 13C-NMR (CD3OD, 100 MHz): See
Table 1. HREI-MSm/z (mol. formula, calcd value):
292.2434 (C19H32O2, 292.2402). EI-MSm/z (rel. int., %):
292 [M+] (66), 277 (51), 259 (33), 241 (20), 217 (54), 215
(100), 201 (14), 173 (11), 165 (45), 147 (33), 107 (47), 93
(48), 55 (37).Fermentation with Gibberella fujikuroi Two stage fer-
mentation protocol (discussed above) was used for the
fermentation of 1 (1.0 g) with G. fujikuroi. Fermentation
medium was prepared as discussed earlier. Fermentation
continued for 7 days. All the flasks were filtered,
extracted with 12 litres of DCM and evaporated in
vacuo. A brown extract (2.5 g) was obtained which was
fractionated over a silica gel column with petroleum
ether- acetone (P.E.- acetone) gradient solvent system.
The fractions were compiled based on thin layer chro-
matography (TLC) profile to obtain five main fractions,
which were again subjected to column chromatography
(C.C.) (P.E.-acetone) and size exclusion high perform-
ance liquid chromatography (HPLC) by using a GS-320
column, and methanol as solvent system to afford pure
metabolites 4–9.Microbial transformation of DHT (1) with G. fujikuroi
The 13C-NMR chemical shifts of compounds 4–9 are
presented in Table 1. Other data is presented below:
Figure 5 Docking conformation of galanthamine (generated by MOE docking software) properly accommodated into the binding
cavity of BChE enzyme and developed hydrogen bond interaction with catalytic residue GLU197 at 2.61 Å.
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crystalline compound. M.p.: 179–181°C (178–182°C
[34]). [α]25D : + 95.0, c = 0.096, MeOH (+94, c = 0.1,
CHCl3 [35]).
1H-NMR (CDCl3, 400 MHz): δ 2.62, dt
(J1a,1e = 14.0 Hz, J1a,2a/2e = 4.0 Hz), 1.98, td (J1e,2a/2e =
13.6 Hz, J1e,1a = 4.0 Hz); 2.41, m; 2.31, m (H-2); 5.71, s
(H-4); 2.37, m; 2.27, m (H-6); 1.81, m; 1.02, m (H-7);
1.56a, m (H-8); 1.05a, m (H-9); 4.02, br. s (W1/2 =
22.0 Hz) (H-11); 1.17, m; 2.13, m (H-12); 1.07a, m (H-
14); 1.58a, m; 1.27, m (H-15); 1.45, m; 2.08, m (H-16);
3.77, t (J17a,16a/16e = 8.0 Hz) (H-17); 0.81, s (H-18); 1.31,
s (H-19), (a = exchangeable assignments). 13C-NMR
(CDCl3, 150 MHz): See Table 1. HREI-MSm/z (mol. for-
mula, calcd value): 304.2058 (C19H28O3, 304.2038). EI-
MSm/z (rel. int., %): 304 [M+] (74), 286 (61), 253 (15),
180 (43), 163 (100), 147 (29), 137 (34), 124 (98), 109
(41), 91 (44), 79 (34), 55 (20).
Androst-1,4-dien-3,17-dione (5). Colorless crystals.
M.p.: 140–142°C (141–142°C [36]). [α]25D : + 115.5 (c =
0.028, MeOH) (+117, CHCl3 [37]).
1H-NMR (CDCl3,
400 MHz): δ 7.03, d (J1,2 = 10.4 Hz) (H-1); 6.22, d (J2,1 =
10.4 Hz) (H-2); 6.07, s (H-4); 2.41a, m, 2.48, m (H-6);
1.12, m, 2.06, m (H-7); 1.80, m (H-8); 1.09, m (H-9);
1.67, m, 1.84, m (H-11); 1.27a, m, 1.87, m (H-12); 1.26a,
m (H-14); 1.57, m, 1.95, m (H-15); 2.10, m, 2.43a, m (H-16);
0.92, s (H-18); 1.24, s (H-19), (a = exchangeable assign-
ments). 13C-NMR (CDCl3, 150 MHz): See Table 1. HREI-
MSm/z (mol. formula, calcd value): 284.1726 (C19H24O2,
284.1776). EI-MSm/z (rel. int., %): 284 [M+] (45), 266 (8),
227 (6), 171 (8), 159 (66), 150 (26), 135 (31), 122 (100), 107
(36), 91 (46), 79 (19), 67 (10), 55 (10).
11α-Hydroxyandrost-4-en-3,17-dione (6). Colorless
crystalline compound. M.p.: 238–239°C (240–241°C[36]). [α]25D : + 162.0, c = 0.034, MeOH (+ 165, CHCl3
[38]). 1H-NMR (CDCl3, 400 MHz): δ 2.05, m; 2.65, dt
(J1a,1e = 13.6 Hz, J1a,2a/2e = 4.4 Hz) (H-1); 2.31
a, m; 2.39,
m (H-2); 5.72, s (H-4); 2.29a, m; 2.37, m (H-6); 1.12, m;
1.97a, m (H-7); 1.68, m (H-8); 1.15, m (H-9); 4.04, m
(W1/2 = 21.5 Hz) (H-11); 1.30, m; 2.11
a, m (H-12); 1.37,
m (H-14); 1.53, m; 1.95a, m (H-15); 2.14a, m; 2.48, m (H-
16); 0.92, s (H-18); 1.31, s (H-19), (a = exchangeable as-
signments). 13C-NMR (CDCl3, 125 MHz): See Table 1.
HREI-MSm/z (mol. formula, calcd value): 302.1852
(C19H26O3, 302.1882). EI-MSm/z (rel. int., %): 302 [M
+]
(24), 290 (35), 280 (21), 248 (51), 230 (95), 215 (21), 198
(19), 186 (28), 159 (31), 139 (100), 138 (88), 136 (52),
105 (29), 87 (65), 55 (18).
11α-Hydroxyandrost-1,4-dien-3,17-dione (7). Color-
less crystalline compound. M.p.: 208–210°C (212–214°C
[34]). [α]25D : + 85.1, c = 0.037, MeOH (+ 86.5 [34]).
1H-
NMR (CDCl3, 300 MHz): δ 7.73, d (J1,2 = 10.2 Hz) (H-1);
6.14, d (J2,1 = 10.2 Hz) (H-2); 6.08, s (H-4); 2.41, m, 2.48,
m (H-6); 1.15, m, 2.07, m (H-7); 1.82, ddd (J8a,9a/14a =
22.8 Hz, J8a,7a = 11.1 Hz, J8a,7e = 3.9 Hz) (H-8); 1.12, m
(H-9); 4.08, m (W1/2 = 19.6 Hz) (H-11); 1.25, m, 2.22, m
(H-12); 1.35, m (H-14); 1.56, m, 1.95, m (H-15); 2.15, m,
2.50, m (H-16); 0.93, s (H-18); 1.31, s (H-19). 13C-NMR
(CDCl3, 150 MHz): See Table 1. HREI-MSm/z (mol. for-
mula, calcd value): 300.1749 (C19H24O3, 300.1725). EI-
MSm/z (rel. int., %): 300 [M+] (36), 282 (18), 231 (80),
161 (20), 124 (37), 109 (32), 84 (58), 55 (23).
12β-Hydroxyandrost-1,4-dien-3,17-dione (8). Color-
less crystalline compound. M.p.: 163–165°C (164–166°C
[39]). [α]25D : + 84.0, c = 0.085, MeOH (+ 83.0, CHCl3
[40]). 1H-NMR (CDCl3, 400 MHz): δ 7.03, d (J1,2 =
10.0 Hz) (H-1); 6.23, dd (J2,1 = 10.0 Hz, J2,4 = 1.2 Hz)
Figure 6 Best selected molecular docking interactions pose of all compounds (1–7) within binding pocket of BChE. Compounds 1–3
exhibited weak interaction due to the absence of π-π interaction (a-c), while compounds 4–7 exhibited strong interactions (d-g) inside the BChE.
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http://journal.chemistrycentral.com/content/7/1/164(H-2); 6.03, br s (H-4); 2.39, m, 2.48, td (13.6, 4.4) (H-6);
1.15, m, 1.92, m (H-7); 1.81, m (H-8); 1.26, m (H-9);
1.42, m, 2.03, m (H-11); 3.73, br s (W1/2 = 13.0 Hz) (H-12);
1.48, m (H-14); 1.75, m, 1.86, m (H-15); 1.90, m, 2.33, m
(H-16); 0.78, s (H-18); 1.25, s (H-19). 13C-NMR (CDCl3,
150 MHz): See Table 1. HREI-MSm/z (mol. formula,calcd value): 300.1737 (C19H24O3, 300.1725). EI-MSm/z
(rel. int., %): 300 [M+] (66), 282 (8), 231 (100), 161 (20),
124 (37), 109 (32), 84 (58), 55 (43).
16α-Hydroxyandrost-1,4-dien-3,17-dione (9). Color-
less crystals. M.p.: 152–153°C. [α]25D : + 89.3 (c = 0.043,
MeOH). 1H-NMR (CDCl3, 400 MHz): δ 7.00, d (J1,2 =
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http://journal.chemistrycentral.com/content/7/1/16410.0 Hz) (H-1); 6.22, d (J2,1 = 10.0 Hz) (H-2); 6.04, s (H-
4); 2.35, m, 2.45, m (H-6); 1.32, m, 2.03, m (H-7); 1.77,
m (H-8); 1.10, m (H-9); 1.67, m, 1.85, m (H-11); 1.37, m,
1.65, m (H-12); 1.50, m (H-14); 1.87, m, 1.98, m (H-15);
4.36, br s (W1/2 = 20.8 Hz) (H-16); 1.01, s (H-18); 1.24, s
(H-19). 13C-NMR (CDCl3, 150 MHz): See Table 1.
HREI-MSm/z (mol. formula, calcd value): 300.1749
(C19H24O3, 300.1725). EI-MSm/z (rel. int., %): 300 [M
+]
(100), 272 (36), 246 (69), 239 (43), 216 (39), 200 (38),
190 (24), 165 (33), 147 (55), 108 (63), 92 (31), 81 (17).
BChE inhibitory assay
All experiments were performed in a 96-well microplate
in triplicate on SpectraMax340 (Molecular Devices, CA,
U. S. A.).
Equine serum BChE, butyrylcholine chloride, and 5,5′-
dithio-bis (2-nitrobenzoic) acid were purchased from
Sigma. Analytical grade buffers and other chemicals were
used. The BChE inhibition was measured by a modified
spectrophotometric method [40]. Butyrylcholine chloride
was used as substrate and the BChE inhibitory activity was
measured by using 5-5′-dithio bis (2-nitrobenzoic) acid
(DTNB).
150 μL of 100 mM sodium phosphate buffer [PBS]
(pH 8), 10 μL of test compound solution (0.2 mM),
and 20 μL BChE solution were mixed together and
incubated at 25°C for 15 minutes. The reaction was
initiated by the addition of 10 μL DTNB and 10 μL of
BCh. A yellow 5-thio-2-nitrobenzoate anion was
formed by hydrolysis of the substrate as a result of
the reaction of DTNB with thiocholine which was
monitored spectrophotometrically at 412 nm. MeOH
was used as a solvent to dissolve the test compounds
and the controls.
Determination of IC50
IC50 values were calculated by measuring the effect of
varying concentrations of test compounds by using the
EZ-Fit Enzyme Kinetic program. Galanthamine was used
as a standard inhibitor of BChE.
Computational methodology
Molecular modeling studies were conducted on a dual pro-
cessor IntelW Xeon™ CPU 3.00 GHz LINUX work station
running under SUSE 11.4. For the selection of best docking
program with respect to the current biological system,
GOLD [41], MOE [42] and Surflex [43,44] docking pro-
grams were employed. Molecular Operating Environment
(MOE) docking software was finally selected to study the
assembly pattern of biotransformed DHT derivatives in
complex with human BChE system. Among thirty-one X-
ray crystal structures of human BChE in the protein data
bank (PDB) [11,45], PDB ID 1P0P: 2.30 Å was selected as
the target protein based on suitable resolution and co-crystallized ligand, BCh. The entire system was energy
minimized by MMFF94 force field [46], after adding the
missing hydrogen atoms and keeping heavy atoms fixed
until a Root-mean-square deviation (RMSD) gradient of
0.05 Kcalmol−1 Å−1 was reached. 3D structures of all me-
tabolites 2–7 were drawn by molecule builder which is in-
corporated in MOE modeling package and the structures
were subjected to MMFF94 for energy minimization. Sub-
sequently for the evaluation of potential energy, partial
charges were calculated by MMFF94 force field [47]. Both
prepared systems (protein and ligand) were introduced
for molecular docking simulation. Docking simulations
were performed by using two methods (a) Alpha Tri-
angle placement method, and (b) Triangle matcher
placement method. All compounds were ranked with
London dG scoring function and re-scored by GBVI/
WSA dG with the force field refinement strategy [48]. A
total of 30 docking poses were generated for each ligand
and the pose with the lowest energy was selected for
further studies.
Conclusion
In summary, we report here the microbial transform-
ation of dihydrotestosterone (DHT, 1) for the first time
by using suspension cultures of M. phaseolina and G.
fujikuroi. Compounds 5–7 were found to be significant
and specific inhibitors of the BChE, in comparison
to standard drug, galanthamine. Current experimental
studies revealed that the DHT derivatives actively partic-
ipated in the inhibition of BChE. Additionally, experi-
mental studies correlated well with theoretical studies
thus indicating the behavior of different metabolites
inside the binding pocket of BChE, and supported inhib-
ition activity trend, followed by least active to highly
active compounds. From the docking analysis, experi-
mental inhibitory potency relationship of compounds 1–
7 exhibited the fundamental role of α,β-unsaturated
carbonyl moiety in ring “A”. In the bound state of me-
tabolites with BChE, compounds 5–7 exhibited favorable
hydrophilic, hydrophobic and hydrogen bond interac-
tions with active site residues of the receptor protein.
These compounds also participated in π-π interaction
towards the TRP82.
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